Treatment of Painful Diabetic Neuropathy Using Frequency Rhythmic Electro Magnetic Neural Stimulation (FREMS); Effectiveness in Daily Practice
Ben Imholz,Jack Heijster,Abd Tahrani,Adriaan Kooy
DOI: https://doi.org/10.2147/DMSO.S401727
2023-05-11
Abstract:Ben Imholz, 1 Jack Heijster, 1 Abd Tahrani, 2 Adriaan Kooy 3 1 Department of Internal Medicine, ETZ Ziekenhuis, Tilburg, the Netherlands; 2 Department of Endocrinology and Diabetes, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; 3 Department of Internal Medicine, Bethesda Hospital, Treant Care Group, Hoogeveen, the Netherlands Correspondence: Ben Imholz, Department of Internal Medicine, ETZ-Location Waalwijk, Kasteellaan 2 5141BM Waalwijk, Tilburg, the Netherlands, Email Background: Painful diabetic peripheral neuropathy (PDPN) is common and difficult to treat with limited treatment options. We assessed the efficacy of frequency rhythmic electromagnetic neural stimulation (FREMS) in patients with PDPN. Methods: An uncontrolled prospective survey of patients with PDPN and pain despite at least two lines of pharmacotherapy. The primary outcome, 50% reduction in pain scores at 1 and/or 3 months post FREMS. FREMS was applied to both legs below the knees using 4 sets of electrodes per leg; the treatment consisted of 10 sessions of 35 min applications given over 14 days. FREMS was repeated every 4 months and patients were followed up for 12 months. Pain was assessed using the neuropathic pain symptom inventory (NPSI) and quality of life (QOL) by the EQ-5D. Results: Out of 336 subjects, 248 patients met the inclusion criteria (56% men), average age and diabetes duration were 65 and 12.6 years respectively. FREMS was associated with a median decrease NPSI of 31% at M1 (range − 100;+93%), and a median decrease of − 37.5% at M3 (range − 100;+250%). The 50% reduction in pain was reached in 80/248 (32.3%) and 87/248 (35.1%) after M1 and M3 respectively. The change in NPSI was accompanied by a decrease in self reported use of opiates of > 50%. Conclusion: FREMS treatment was associated with a significant reduction in pain severity over a three months period in patients who did not have adequate response to pharmacotherapy. Randomised (sham)-controlled trials examining the role of FREMS as a treatment for PDPN in non-responders to pharmacotherapy are needed. Keywords: diabetic neuropathy, electrical stimulation, FREMS, NPSI pain score, quality of life, one-year follow-up Electrical stimulation by means of the frequency rhythmic electromagnetic neural stimulation (FREMS) characteristics was not earlier reported in a large population of patients, inadequately treated with classical treatment options for painful diabetic neuropathy (DN). The survey shows real-life data in 248 patients. The data show a significant effect after 10 days of treatment lasting for 4 months. In subjects defined as responders, the effect persisted with two additional 10 day treatment sessions during a one-year follow-up. In these subjects a significant >50% decrease in medication use such as morphine was documented. Our survey indicates FREMS as a possible treatment option in difficult to treat painful DN. Painful diabetic peripheral neuropathy (PDPN) is common and affects 20–30% of patients with diabetes mellitus (DM) in Europe with higher prevalence in Africa and the Middle East. 1 Different international, European and North American guidelines have generally recommended tricyclic agents (TCA), serotonin–norepinephrine reuptake inhibitors (SNRIs), and γ-aminobutyric acid (GABA) analogues as first and second line treatment, the order of which differs between the different guidelines as does the recommendations to use morphine or tramadol. 2 Despite the above-mentioned treatments, a significant proportion of patients with PDPN do not respond to treatments (up to 75%) and need more sophisticated regimens to relieve pain. 1–3 In addition, the economic impact of PDPN is significant with an estimated health care cost of 2000–4000 euros per year and loss of productivity cost of 6000–17,000 euros per year depending on pain severity. 4 Hence, new modalities for treatment are needed. Frequency rhythmic electromagnetic neural stimulation (FREMS) is a characteristic type of nerve stimulation (FremsLife, Genua, Italy). The signal is free from nerve adaptation since it uses sequences of modulated electrical stimuli that vary automatically in terms of pulse frequency, duration and voltage amplitude. The FREMS method was designed on the basis of the hypothesis that the summation of sub-threshold electrical stimuli, conveyed through the skin proximal to a motor nerve in a non-invasive system, would induce composite motor action potentials in excitable tissues. A single impulse of low intensity and short duration, such as that used by conventional electrotherapies, is unable to overcome the dielectric skin barrier to excite the underlying ne -Abstract Truncated-
endocrinology & metabolism